277 related articles for article (PubMed ID: 18248310)
1. Eicosanoids and renal damage in cardiometabolic syndrome.
Imig JD
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):165-74. PubMed ID: 18248310
[TBL] [Abstract][Full Text] [Related]
2. Cardiometabolic syndrome and chronic kidney disease: what is the link?
Sarafidis PA; Whaley-Connell A; Sowers JR; Bakris GL
J Cardiometab Syndr; 2006; 1(1):58-65. PubMed ID: 17675896
[TBL] [Abstract][Full Text] [Related]
3. Epoxyeicosanoids in hypertension.
Imig JD
Physiol Res; 2019 Oct; 68(5):695-704. PubMed ID: 31475560
[TBL] [Abstract][Full Text] [Related]
4. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
5. Introduction: organ involvement in the cardiometabolic syndrome.
Hayden MR; Stump CS; Sowers JR
J Cardiometab Syndr; 2006; 1(1):16-24. PubMed ID: 17675904
[TBL] [Abstract][Full Text] [Related]
6. The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
Chiamvimonvat N; Ho CM; Tsai HJ; Hammock BD
J Cardiovasc Pharmacol; 2007 Sep; 50(3):225-37. PubMed ID: 17878749
[TBL] [Abstract][Full Text] [Related]
7. The contribution of chymase-dependent formation of ANG II to cardiac dysfunction in metabolic syndrome of young rats: roles of fructose and EETs.
Froogh G; Kandhi S; Duvvi R; Le Y; Weng Z; Alruwaili N; Ashe JO; Sun D; Huang A
Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H985-H993. PubMed ID: 32167781
[TBL] [Abstract][Full Text] [Related]
8. Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice.
Roche C; Besnier M; Cassel R; Harouki N; Coquerel D; Guerrot D; Nicol L; Loizon E; Remy-Jouet I; Morisseau C; Mulder P; Ouvrard-Pascaud A; Madec AM; Richard V; Bellien J
Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1020-9. PubMed ID: 25724490
[TBL] [Abstract][Full Text] [Related]
9. Eicosanoids in metabolic syndrome.
Hardwick JP; Eckman K; Lee YK; Abdelmegeed MA; Esterle A; Chilian WM; Chiang JY; Song BJ
Adv Pharmacol; 2013; 66():157-266. PubMed ID: 23433458
[TBL] [Abstract][Full Text] [Related]
10. Epoxylipids and soluble epoxide hydrolase in heart diseases.
Imig JD; Cervenka L; Neckar J
Biochem Pharmacol; 2022 Jan; 195():114866. PubMed ID: 34863976
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor.
Smith KR; Pinkerton KE; Watanabe T; Pedersen TL; Ma SJ; Hammock BD
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2186-91. PubMed ID: 15684051
[TBL] [Abstract][Full Text] [Related]
12. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
13. [Cardiovascular consequences of chronic kidney disease, impact of modulation of epoxyeicosatrienoic acids].
Hamzaoui M; Guerrot D; Djerada Z; Duflot T; Richard V; Bellien J
Ann Cardiol Angeiol (Paris); 2018 Jun; 67(3):141-148. PubMed ID: 29793671
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.
Imig JD
Cardiovasc Drug Rev; 2006; 24(2):169-88. PubMed ID: 16961727
[TBL] [Abstract][Full Text] [Related]
15. Update on the cardiometabolic syndrome.
Sowers JR
Clin Cornerstone; 2001; 4(2):17-23. PubMed ID: 11838324
[TBL] [Abstract][Full Text] [Related]
16. A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes.
Hye Khan MA; Kolb L; Skibba M; Hartmann M; Blöcher R; Proschak E; Imig JD
Diabetologia; 2018 Oct; 61(10):2235-2246. PubMed ID: 30032428
[TBL] [Abstract][Full Text] [Related]
17. Cardiometabolic syndrome and chronic kidney disease.
Lastra G; Manrique C; McFarlane SI; Sowers JR
Curr Diab Rep; 2006 Jun; 6(3):207-12. PubMed ID: 16898573
[TBL] [Abstract][Full Text] [Related]
18. Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.
Roche C; Guerrot D; Harouki N; Duflot T; Besnier M; Rémy-Jouet I; Renet S; Dumesnil A; Lejeune A; Morisseau C; Richard V; Bellien J
Prostaglandins Other Lipid Mediat; 2015 Jul; 120():148-54. PubMed ID: 26022136
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Červenka L; Melenovský V; Husková Z; Škaroupková P; Nishiyama A; Sadowski J
Clin Exp Pharmacol Physiol; 2015 Jul; 42(7):795-807. PubMed ID: 25969338
[TBL] [Abstract][Full Text] [Related]
20. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL
Circ Res; 2000 Nov; 87(11):992-8. PubMed ID: 11090543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
